Brief: Cancer Research UK Says Dosed First Patient In Phase I/Iia Trial Of Lung Cancer Immunotherapy Vaccine
18/01/2022 08:03
Jan 18 (Reuters) -
* CANCER RESEARCH UK DOSE FIRST PATIENT IN PHASE I/IIA TRIAL
OF
LUNG CANCER IMMUNOTHERAPY VACCINE
Source text for Eikon: ID:nGNXbnvcBZ
Further company coverage: VACC.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing